Ovarian Cancer

Latest News

Female Asian patient at doctor | Image Credit: DragonImages - stock.adobe.com
Ovarian Cancer Survival Varies Widely Among Asian American Subgroups

November 13th 2024

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the importance of analyzing these groups separately.

HPV written in blocks | Image Credit: Iana Alter - stock.adobe.com
HPV 16 and 18 Linked to Ovarian Cancer Risk

October 29th 2024

Balanced diet | Image Credit: nadianb - stock.adobe.com
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer

October 24th 2024

Patient with ovarian cancer | Image Credit: Kiattisak - stock.adobe.com
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer

October 22nd 2024

Air pollution | Image Credit: hramovnick - stock.adobe.com
Increased Ovarian Cancer Risk Linked to Elevated Nitrogen Dioxide Exposure, Study Finds

October 18th 2024

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

More News

Filling a syringe with IV drug | Image Credit: PhotobyTawat – stock.adobe.com
October 30th 2023

EMA Accepts Marketing Authorization Application for Mirvetuximab Soravtansine in FRα+, Platinum-Resistant Ovarian Cancer

Chris Ryan
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
ovarian cancer | Image credit: Crystal light - stock.adobe.com
October 20th 2023

Cell-Free Liquid Biopsy Test for Ovarian Cancer Proves 91% Accurate

Skylar Jeremias
A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer.
AJMC
October 17th 2023

Association of Guideline-Concordant Care With Survival, Health Care Utilization, and Costs Among Older Women With Advanced Epithelial Ovarian Cancer

Shweta Kamat, MS Britny R. Brown, PharmD Anne Hume, PharmD Ami Vyas, PhD, MS, MBA
Non–guideline-concordant care for ovarian cancer was associated with higher all-cause and cancer-specific mortality, increased health care utilization, and increased Medicare expenditures, highlighting opportunities for improving cancer care in this vulnerable group.
Surgeon holding scalpel near ovary | Image Credit: shidlovski – stock.adobe.com
October 13th 2023

Algorithm Reduces Unnecessary Oophorectomies in Pediatric Patients

Hayden E. Klein
The preoperative risk assessment algorithm can identify ovarian lesions with a strong likelihood of being non-cancerous and suitable for ovary-preserving surgery.
Rebecca Brooks, MD | Image Credit: UC Davis Health
October 4th 2023

Dr Rebecca Brooks Gives Expert Advice, Resources for Patients With or at High Risk of Ovarian Cancer

Hayden E. Klein
More ovarian cancer drug approvals and treatments have become available since 2014 than in the preceding 60 years combined, emphasized Rebecca Brooks, MD, UC Davis Health.
female reproductive system | Image credit: magicmine – stock.adobe.com
September 30th 2023

FDA Grants Fast Track Designation to IDE161 for BRCA+, Platinum-Resistant Advanced Ovarian Cancer

Chris Ryan
The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and poly-ADP ribose polymerase, or PARP, inhibitor therapies.
Rebecca Brooks, MD
September 29th 2023

Dr Rebecca Brooks Covers Ovarian Cancer Risk Factors, Preventive Measures

Hayden E. Klein
Family history is probably the biggest risk factor that patients need to know about, said Rebecca Brooks, MD, UC Davis Health.
PFAS | Image credit: Francesco Scatena – stock.adobe.com
September 27th 2023

"Forever" Chemical Levels Higher in Women With Ovarian, Breast, Other Cancers

Hayden E. Klein
Women with ovarian, breast, skin, and uterine cancers were found to have significantly higher levels of per- and polyfluoroalkyl substances (PFAS), phenols, and parabens in their bodies.
female reproductive anatomy | Image credit: magicmine – stock.adobe.com
September 25th 2023

NACT Use Appears to Be Increasing in Less Common Epithelial Ovarian Cancers

Nicholas Wrigley
Patients with low-grade serous ovarian cancer appear to have worse survival outcomes following treatment with neoadjuvant chemotherapy (NACT).
ovarian cancer | Image credit: blueringmedia – stock.adobe.com
September 23rd 2023

Innovative Combination Therapy Shows Promise for Late-Stage Ovarian Cancer

Hayden E. Klein
The treatment combined adoptive T-cell therapy with a personalized cancer vaccine and was found to be safe in a small cohort of 17 patients.
3d illustration of ovarian cancer | Image credit: Lars Neumann – stock.adobe.com
September 12th 2023

Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer

Hayden E. Klein
Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
tumor on the ovarian | Image credit: blueringmedia - stock.adobe.com
September 9th 2023

TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer

Caroline Seymour
The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.
emergency department
September 6th 2023

Study Highlights Factors Linked to ED Readmission Following Ovarian Carcinoma Surgery

Hayden E. Klein
Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.
Ultrasonography-Based Ovarian Tumor Risk Models Show High Performance in US Cohort
August 31st 2023

Ultrasonography-Based Ovarian Tumor Risk Models Show High Performance in US Cohort

Rose McNulty
A recent study found that ultrasonography-based risk models for differentiation between benign and malignant ovarian tumors performed well in a diagnostic study conducted in a US cohort.
A diagnostic form with words Ovarian cancer: © Vitalii Vodolazskyi - stock.adobe.com
August 26th 2023

Genomic Analysis Reveals Complex Alterations in HGSC

Jared Kaltwasser
Investigators said analysis of multiple tissues from the same patients suggests tumor evolution in high-grade serous ovarian cancer (HGSC) was not through somatic mutations.
what we're reading logo
August 16th 2023

What We’re Reading: Drug Shortage Impacts Cancer Treatment; Consequences for Medicaid Money Misuse; Helping Children With Mental Illness

AJMC Staff
The platinum drugs most effective in treating ovarian cancer are in limited supply due to the drug shortage; the government proposes a plan to prevent hospitals from redistributing Medicaid money; physicians ask for help in treating the high number of children with mental illness coming to the emergency department.
Female Reproductive System Anatomy | Image Credit: nerthuz – stock.adobe.com
August 11th 2023

Fallopian Tube Removal Not Linked to Ovarian Cancer Risk, Study Says

Hayden E. Klein
New research found that ovarian cancer risk is reduced by salpingectomy just as much as by tubal ligation, contradicting guidelines that suggest otherwise.
GYM AEROBIC CLASS DOING EXERCISE | Image Credit: godfer – stock.adobe.com
August 9th 2023

Exercise May Reduce Chemotherapy-Induced Peripheral Neuropathy Symptoms in Women With Ovarian Cancer

Hayden E. Klein
While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.
genetic research
August 4th 2023

64-Protein Signature May Predict Ovarian Cancer Response to Chemotherapy

Hayden E. Klein
Mount Sinai researchers discovered a 64-protein signature that may help predict whether patients with high-grade serous ovarian cancers will respond to chemotherapy.
ovarian cancer
August 2nd 2023

Niraparib Maintenance Therapy Improves PFS by 55% in Advanced Ovarian Cancer

Hayden E. Klein
Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.
Doctor or psychiatrist consulting and diagnostic examining stressful woman patient on obstetric - gynecological female illness, or mental health in medical clinic or hospital healthcare service center: © Chinnapong - stock.adobe.com
July 30th 2023

Case Study Details Rare Instance of Ovarian SCC Resulting From Endometriosis

Gianna Melillo
Currently, there is no established standard of care treatment for ovarian squamous cell carcinoma (SCC).
Checkup uterus reproductive system , women's health, PCOS, ovary cancer treatment and examine, Healthy feminine concept: © Kiattisak - stock.adobe.com
July 27th 2023

Review Outlines Barriers to Guideline-Adherent Ovarian Cancer Care

Gianna Melillo
Racial minority patients and low socioeconomic status patients tended to face the most barriers.
Ovarian cancer
July 22nd 2023

Tumor Differences Associated With Survival Outcomes in HGSC Ovarian Cancer

Jared Kaltwasser
Investigators looked at both primary and metastatic tumors and found correlations between characteristics and patient outcomes.
Female Reproductive System Anatomy: © mi_viri - stock.adobe.com
July 19th 2023

In Ovarian Cancer, Postchemotherapy Immunological Modification Points to Later Relapse

Jared Kaltwasser
Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage.
Chemotherapy
July 15th 2023

NACT Use Is Growing in Rare Ovarian Cancers, but Certain Patients May Not Benefit

Jaime Rosenberg
The findings come amidst growing use of the treatment approach.
OVARIAN CANCER CONCEPT: © onephoto - stock.adobe.com
July 13th 2023

Survey Details Concerns, Priorities of Women With Ovarian Cancer

Gianna Melillo
In addition to a fear of cancer recurrence, patients said feeling isolated was also a challenge associated with having ovarian cancer.
Ovarian cancer, 3D illustration: © Dr_Microbe - stock.adobe.com
July 7th 2023

Nurse Navigators Improve Rate, Timeliness of NGS in Ovarian Cancer

Jared Kaltwasser
Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.
ovarian cancer circled | blueringmedia - stock.adobe.com
July 3rd 2023

Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer: Review

Gianna Melillo
Outcomes for patients with this form of the disease are poor and treatment options are limited.
Kathleen Moore, MD, MS
June 30th 2023

Kathleen N. Moore, MD, MS, on Groundbreaking Result in MIRASOL: “This Is What Patients Want”

Interview by Mary Caffrey
This interview with the lead investigator of the MIRASOL trial, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will appear with coverage of ASCO in the upcoming issue of Evidence-Based Oncology.
data points overlaid on icons of people
June 26th 2023

Barriers, Facilitators of Breast, Ovarian Screening Tool Implementation in Community-Based Organizations

Gianna Melillo
Latina women at risk of hereditary breast and ovarian cancer are less likely to be referred for genetic counseling and testing.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo